Financial Advocates Investment Management Sells 2,120 Shares of Zoetis Inc. $ZTS

Financial Advocates Investment Management cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 34.6% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,016 shares of the company’s stock after selling 2,120 shares during the quarter. Financial Advocates Investment Management’s holdings in Zoetis were worth $626,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Scott & Selber Inc. boosted its position in shares of Zoetis by 0.6% in the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after purchasing an additional 67 shares in the last quarter. Secure Asset Management LLC increased its holdings in Zoetis by 2.9% in the 2nd quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock worth $382,000 after buying an additional 68 shares in the last quarter. Moment Partners LLC raised its holdings in shares of Zoetis by 3.2% during the second quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock valued at $367,000 after purchasing an additional 72 shares during the last quarter. CVA Family Office LLC raised its stake in Zoetis by 6.7% during the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock valued at $183,000 after buying an additional 74 shares during the last quarter. Finally, Menard Financial Group LLC increased its position in Zoetis by 3.8% during the first quarter. Menard Financial Group LLC now owns 2,032 shares of the company’s stock valued at $305,000 after acquiring an additional 75 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $127.78 on Thursday. The company has a market capitalization of $56.31 billion, a price-to-earnings ratio of 21.99, a PEG ratio of 2.31 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The stock’s 50-day simple moving average is $136.51 and its 200-day simple moving average is $149.48. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $181.85.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same quarter last year, the business posted $1.58 earnings per share. The firm’s revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.6%. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of research reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. UBS Group decreased their price target on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. BTIG Research cut their price objective on shares of Zoetis from $200.00 to $160.00 and set a “buy” rating for the company in a research report on Wednesday, November 12th. JPMorgan Chase & Co. reduced their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, KeyCorp started coverage on Zoetis in a report on Thursday, November 20th. They issued a “sector weight” rating on the stock. Six equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.